Download MendeleyEvolution and synthesis of novel orally bioavailable inhibitors of PDE10A.
Burdi, D.F., Campbell, J.E., Wang, J., Zhao, S., Zhong, H., Wei, J., Campbell, U., Shao, L., Herman, L., Koch, P., Jones, P.G., Hewitt, M.C.(2015) Bioorg Med Chem Lett 25: 1864-1868
- PubMed: 25863433
- DOI: https://doi.org/10.1016/j.bmcl.2015.03.050
- Primary Citation of Related Structures:
4YQH, 4YS7 - PubMed Abstract:
The design and synthesis of highly potent, selective orally bioavailable inhibitors of PDE10A is reported. Starting with an active compound of modest potency from a small focused screen, we were able to evolve this series to a lead molecule with high potency and selectivity versus other PDEs using structure-based design. A systematic refinement of ADME properties during lead optimization led to a lead compound with good half-life that was brain penetrant. Compound 39 was highly potent versus PDE10A (IC50=1.0 nM), demonstrated high selectivity (>1000-fold) against other PDEs and was efficacious when dosed orally in a rat model of psychosis, PCP-induced hyperlocomotion with an EC50 of 1 mg/kg.
Organizational Affiliation:
Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA 01752, United States. Electronic address: douglas.burdi@sunovion.com.
